Decreased serum arylesterase activity in autism spectrum disorders

Psychiatry Research

Volumn 180, Issue 2-3, 2010, Pages 105-113

  Gaita, Laura ^a,b   Manzi, Barbara ^c   Sacco, Roberto ^a,b   Lintas, Carla ^a,b   Altieri, Laura ^a,b   Lombardi, Federica ^a,b   Pawlowski, Tracy L ^d   Redman, Margot ^d   Craig, David W ^d   Huentelman, Matthew J ^d   Ober Reynolds, Sharman ^e   Brautigam, Sarah ^e   Melmed, Raun ^e   Smith, Christopher J ^e   Marsillach, Judith ^f   Camps, Jordi ^f   Curatolo, Paolo ^c   Persico, Antonio M ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e Southwest Autism Research and Resource Center   (United States)

^f Saint Joan University Hospital   (Spain)

Author keywords

Autistic disorder; Diazoxonase; Immune; Organophosphate; Paraoxonase; Pervasive developmental disorders

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; DIAZOXONASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTISM; CHILD; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME SPECIFICITY; ETHNIC DIFFERENCE; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC TESTING; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77953807975     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.010     Document Type: Article

References (69)

1. Abramson R.K., Wright H.H., Carpenter R., Brennan W., Lumpuy O., Cole E., Young S.R. Elevated blood serotonin in autistic probands and their first-degree relatives. Journal of Autism and Developmental Disorders 1989, 19:397-407.
2. Ahmed Z., Babaei S., Maguire G.F., Draganov D., Kuksis A., La Du B.N., Connelly P.W. Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovascular Research 2003, 57:225-231.
3. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
4. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. Journal of Leukocyte Biology 2006, 80:1-15.
5. Augustinsson K.B., Barr M. Age variation in plasma arylesterase activity in children. Clinica Chimica Acta 1963, 8:568-573.
6. Bauman M.L., Kemper T.L. Neuroanatomic observations of the brain in autism: a review and future directions. International Journal of Developmental Neuroscience 2005, 23:183-187.
7. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., Furlong C.E. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics 2001, 68:1428-1436.
8. Camps J., Marsillach J., Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Reviews in Medicinal Chemistry 2009, 9:911-920.
9. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology 2006, 13:171-181.
10. Chen J., Kumar M., Chan W., Berkowitz G., Wetmur J.G. Increased influence of genetic variation on PON1 activity in neonates. Environmental Health Perspectives 2003, 111:1403-1409.
11. Cole T.B., Jampsa R.L., Walter B.J., Arndt T.L., Richter R.J., Shih D.M., Tward A., Lusis A.J., Jack R.M., Costa L.G., Furlong C.E. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003, 13:357-364.
12. Conciatori M., Stodgell C.J., Hyman S.L., O'Bara M., Militerni R., Bravaccio C., Trillo S., Montecchi F., Schneider C., Melmed R., Elia M., Crawford L., Spence S.J., Muscarella L., Guarnieri V., D'Agruma L., Quattrone A., Zelante L., Rabinowitz D., Pascucci T., Puglisi-Allegra S., Reichelt K.L., Rodier P.M., Persico A.M. Morphogenetic effect of the HOXA1 A218G polymorphism on head circumference in patients with autism. Biological Psychiatry 2004, 55:413-419.
13. Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., Furlong C.E. The role of paraoxonase (PON1) in the detoxification of organophosphates and its human polymorphism. Chemico-Biological Interactions 1999, 119-120:429-438.
14. D'Amelio M., Ricci I., Sacco R., Liu X., D'Agruma L., Muscarella L.A., Guarnieri V., Militerni R., Bravaccio C., Elia M., Schneider C., Melmed R., Trillo S., Pascucci T., Puglisi-Allegra S., Reichelt K.L., Macciardi F., Holden J.J., Persico A.M. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Molecular Psychiatry 2005, 10:1006-1016.
15. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. Journal of Lipid Research 2005, 46:1239-1247.
16. Ferré N., Camps J., Fernández-Ballart J., Arija V., Murphy M.M., Ceruelo S., Biarnés E., Vilella E., Tous M., Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clinical Chemistry 2003, 49:1491-1497.
17. Ferré N., Marsillach J., Camps J., Rull A., Coll B., Tous M., Joven J. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clinica Chimica Acta 2005, 361:206-210.
18. Furlong C.E., Richter R.J., Seidel S.L., Motulsky A.G. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. American Journal of Human Genetics 1988, 43:230-238.
19. Furlong C.E., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Alleva E., Costa L.G. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 2000, 21:91-100.
20. Garbett K., Ebert P.J., Mitchell A., Lintas C., Manzi B., Mirnics K., Persico A.M. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiology of Disease 2008, 30:303-311.
21. Geschwind D.H., Sowinski J., Lord C., Iversen P., Shestack J., Jones P., Ducat L., Spence S.J., Steering Committee A.G.R.E. The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. American Journal of Human Genetics 2001, 69:463-466.
22. Horvath S., Xu X., Lake S.L., Silverman E.K., Weiss S.T., Laird N.M. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genetic Epidemiology 2004, 26:61-69.
23. Hu F.B., Willet W.C. Optimal diets for prevention of coronary heart disease. Journal of the American Medical Association 2002, 288:2569-2578.
24. Huen K., Richter R., Furlong C., Eskenazi B., Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clinica Chimica Acta 2009, 402:67-74.
25. Huen K., Harley K., Brooks J., Hubbard A., Bradman A., Eskenazi B., Holland N. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphysms. Environmental Health Prospectives 2009, 117:1632-1638.
26. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993, 3:73-76.
27. James S.J., Melnyk S., Jernigan S., Cleves M.A., Halsted C.H., Wong D.H., Cutler P., Bock K., Boris M., Bradstreet J.J., Baker S.M., Gaylor D.W. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2006, 141B:947-956.
28. Janel N., Robert K., Chabert C., Ledrù A., Gouédard C., Barouki R., Delabar J.M., Chassé J.F. Mouse liver paraoxonase-I gene expression is down-regulated in hyperhomocysteinemia. Thrombosis and Haemostasis 2004, 92:221-222.
29. Janel N., Robert K., Demuth K., Gouédard C., Barouki R., Chassé J.F. Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans. Thrombosis and Haemostasis 2005, 93:182-183.
30. Jarvik G.P., Tsai N.T., McKinstry L.A., Wani R., Brophy V.H., Richter R.J., Schellenberg G.D., Heagerty P.J., Hatsukami T.S., Furlong C.E. Vitamin C and E intake is associated with increased paraoxonase activity. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:1329-1333.
31. Kitchen B.J., Masters C.J., Winzor D.J. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. The Biochemical Journal 1973, 135:93-99.
32. La Du B.N., Aviram M., Billecke S., Navab M., Primo-Parmo S., Sorenson R.C., Standiford T.J. On the physiological role(s) of the paroxonases. Chemico-Biological Interactions 1999, 119-120:379-388.
33. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
34. Lintas C., Sacco R., Garbett K., Mirnics K., Militerni R., Bravaccio C., Curatolo P., Manzi B., Schneider C., Melmed R., Elia M., Pascucci T., Puglisi-Allegra S., Reichelt K.-L., Persico A.M. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Molecular Psychiatry 2009, 46:1-8.
35. Lintas C., Altieri L., Lombardi F., Sacco R., Persico A.M. Association of autism with polyomavirus infection in postmortem brains. Journal of Neurovirology 2010, (Electronic publication ahead of print, Mar 29). 10.3109/13550281003685839.
36. Lord C., Rutter M., DiLavore P.C., Risi S. ADOS, Autism Diagnostic Observation Schedule 2002, Western Psychological Services, Los Angeles, (Italian version ed. by Tancredi, R., Saccani, M., Persico, A.M., Parrini, B., Igliozzi, R., Faggioli, R., 2005. Organizzazioni Speciali, Florence).
37. Marsillach J., Mackness B., Mackness M., Riu F., Beltrán R., Joven J., Camps J. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radical Biology and Medicine 2008, 45:146-157.
38. Marsillach J., Parra S., Ferré N., Coll B., Alonso-Villaverde C., Joven J., Camps J. Paraoxonase-1 in chronic liver diseases, neurological disease and HIV infection. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism 2008, Springer, Dordrecht. B. Mackness, M. Mackness, M. Aviram, G. Paragh (Eds.).
39. Marsillach J., Camps J., Ferré N., Beltrán R., Rull A., Mackness B., Mackness M., Joven J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 2009, 9:3.
40. Melke J., Goubran Botros H., Chaste P., Betancur C., Nygren G., Anckarsäter H., Rastam M., Ståhlberg O., Gillberg I.C., Delorme R., Chabane N., Mouren-Simeoni M.C., Fauchereau F., Durand C.M., Chevalier F., Drouot X., Collet C., Launay J.M., Leboyer M., Gillberg C., Bourgeron T. Abnormal melatonin synthesis in autism spectrum disorders. Molecular Psychiatry 2008, 13:90-98.
41. Miller M.T., Stromland K., Ventura L., Johansson M., Bandim J.M., Gillberg C. Autism associated with conditions characterized by developmental errors in early embryogenesis: a mini review. International Journal of Developmental Neuroscience 2005, 23:201-219.
42. Mohamed Ali S., Chia S.E. Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populations-a short review. Industrial Health 2008, 46:309-317.
43. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A.G. Plasma paraoxonase polymorphisms: a new enzyme assay, population, family, biochemical, and linkage studies. American Journal of Human Genetics 1983, 35:393-408.
44. Nguyen S.D., Sok D.E. Beneficial effect of oleoylated lipids on paraoxonase-1: protection against oxidative inactivation and stabilization. The Biochemical Journal 2003, 375:275-285.
45. Palmieri L., Papaleo V., Porcelli V., Scarcia P., Gaita L., Sacco R., Hager J., Rousseau F., Curatolo P., Manzi B., Militerni R., Bravaccio C., Trillo S., Schneider C., Melmed R., Elia M., Lenti C., Saccani M., Pascucci T., Puglisi-Allegra S., Reichelt K.L., Persico A.M. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Molecular Psychiatry 2010, 15:38-52.
46. Parra S., Alonso-Villaverde C., Coll B., Ferré N., Marsillach J., Aragonès G., Mackness M., Mackness B., Masana L., Joven J., Camps J. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007, 194:175-181.
47. Pasça S.P., Nemes B., Vlase L., Gagyi C.E., Dronca E., Miu A.C., Dronca M. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sciences 2006, 78:2244-2248.
48. Pasça S.P., Dronca E., Kaucsár T., Craciun E.C., Endreffy E., Ferencz B.K., Iftene F., Benga I., Cornean R., Banerjee R., Dronca M. One carbon metabolism disturbances and the C667T MTHFR gene polymorphism in children with autism spectrum disorders. Journal of Cellular and Molecular Medicine 2010, 13:4229-4238.
49. Paşca S.P., Dronca E., Nemeş B., Kaucsár T., Endreffy E., Iftene F., Benga I., Cornean R., Dronca M. Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. Journal of Cellular and Molecular Medicine 2010, 14:600-6007.
50. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends in Neurosciences 2006, 29:349-358.
51. Piven J., Palmer P., Jacobi D., Childress D., Arndt S. Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. The American Journal of Psychiatry 1997, 154:185-190.
52. Playfer J.R., Eze L.C., Bullen M.F., Evans D.A. Genetic polymorphism and interethnic variability of plasma paroxonase activity. Journal of Medical Genetics 1976, 13:337-342.
53. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
54. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
55. Richter R., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
56. Roberts E.M., English P.B., Grether J.K., Windham G.C., Somberg L., Wolff C. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environmental Health Perspectives 2007, 115:1482-1489.
57. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatrica 2005, 94:2-15.
58. Rutter M., Le Couter A., Lord C. ADI-R, Autism Diagnostic Interview-Revised 2003, Western Psychological Services, Los Angeles, (Italian version ed. by Faggioli, R., Saccani, M., Persico, A.M., Tancredi, R., Parrini, B., Igliozzi, R., 2005. Organizzazioni Speciali, Florence).
59. Sacco R., Papaleo V., Hager J., Rousseau F., Moessner R., Militerni R., Bravaccio C., Trillo S., Schneider C., Melmed R., Elia M., Curatolo P., Manzi B., Pascucci T., Puglisi-Allegra S., Reichelt K.-L., Persico A.M. Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1. BMC Medical Genetics 2007, 8:11.
60. Sham P.C., Curtis D. Monte Carlo tests for association between disease and alleles at highly polymorphic loci. Annals of Human Genetics 1995, 59:97-105.
61. Shih D.M., Gu L., Xia Y.-R., Navab M., Li W.-F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
62. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arteriosclerosis, Thrombosis, and Vascular Biology 1999, 19:2214-2225.
63. Sutherland W.H.F., Walker R.J., de Jong S.A., van Rij A.M., Phillips V., Walker H.L. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arteriosclerosis, Thrombosis, and Vascular Biology 1999, 19:1340-1347.
64. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
65. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 103:2283-2288.
66. Van Lenten B.J., Wagner A.C., Anantharamaiah G.M., Garber D.W., Fishbein M.C., Adhikary L., Nayak D.P., Hama S., Navab M., Fogelman A.M. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002, 106:1127-1132.
67. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology 2005, 57:67-81.
68. Whyett R.M., Barr D.B. Measurement of organophosphate metabolites in postpartum meconium as a potential biomarker of prenatal exposure: a validation study. Environmental Health Perspectives 2001, 109:417-420.
69. Yang M.S., Gill M. A review of gene linkage, association and expression studies in autism and an assessment of convergent evidence. International Journal of Developmental Neuroscience 2007, 25:69-85.